OTCMKTS:PMCB PharmaCyte Biotech Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.24 0.00 (0.00%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$2.23▼$2.3150-Day Range$2.01▼$2.3352-Week Range$1.79▼$21.00Volume120,426 shsAverage Volume210,679 shsMarket Capitalization$46.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest PharmaCyte Biotech MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.24) to ($0.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.58 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for PharmaCyte Biotech. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for PMCB. Previous Next 0.0 Dividend Strength Dividend YieldPharmaCyte Biotech does not currently pay a dividend.Dividend GrowthPharmaCyte Biotech does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PMCB. Previous Next 1.7 News and Social Media Coverage News SentimentPharmaCyte Biotech has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.Search Interest2 people have searched for PMCB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added PharmaCyte Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PharmaCyte Biotech insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 10.87% of the stock of PharmaCyte Biotech is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for PharmaCyte Biotech are expected to grow in the coming year, from ($0.24) to ($0.18) per share.Price to Book Value per Share RatioPharmaCyte Biotech has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address About PharmaCyte Biotech (OTCMKTS:PMCB) StockPharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cells. It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. The company has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is based in Laguna Hills, California.Read More PMCB Stock News HeadlinesJune 23, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJuly 3, 2022 | Vantage Point (Ad)How You Should Be Choosing Your StocksGrab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2. June 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoJune 8, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueApril 27, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesApril 19, 2022 | marketwatch.comPharmaCyte Biotech Shares Reverse Course, Drop 8%April 19, 2022 | finance.yahoo.comPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsJuly 3, 2022 | Vantage Point (Ad)How You Should Be Choosing Your StocksGrab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2. April 13, 2022 | seekingalpha.comPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdApril 13, 2022 | finance.yahoo.comPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialApril 5, 2022 | finance.yahoo.comPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsMarch 22, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateMarch 18, 2022 | seekingalpha.comPharmaCyte Biotech reports Q3 resultsMarch 16, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Third Quarter Financial Results and Operational HighlightsFebruary 22, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationFebruary 14, 2022 | finance.yahoo.comPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDAJanuary 4, 2022 | finance.yahoo.comPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsDecember 16, 2021 | benzinga.comPharmaCyte Biotech Reports Q2 2021 Cash On Hand $87MDecember 15, 2021 | finance.yahoo.comPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational HighlightsSeptember 27, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNASeptember 21, 2021 | finance.yahoo.comPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility TestsSeptember 16, 2021 | benzinga.comThinking about buying stock in Camber Energy, Farmmi, Offerpad Solutions, Pharmacyte Biotech, or Barrick Gold?September 16, 2021 | finance.yahoo.comPharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDASeptember 8, 2021 | finance.yahoo.comPharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceAugust 31, 2021 | finance.yahoo.comPharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability StudyAugust 25, 2021 | finance.yahoo.comPharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital RaiseSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PMCB CUSIPN/A CIK1157075 Webwww.pharmacyte.com Phone(917) 595-2850Fax917-595-2851Employees4Year FoundedN/ACompany Calendar Last Earnings12/15/2021Today7/03/2022Fiscal Year End4/30/2023Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3.55 million Net MarginsN/A Pretax MarginN/A Return on Equity-7.71% Return on Assets-7.62% Debt Debt-to-Equity RatioN/A Current Ratio141.62 Quick Ratio141.62 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.00 per share Price / Book0.56Miscellaneous Outstanding Shares20,720,000Free FloatN/AMarket Cap$46.41 million OptionableNot Optionable Beta-0.02 PharmaCyte Biotech Frequently Asked Questions Should I buy or sell PharmaCyte Biotech stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PharmaCyte Biotech in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PharmaCyte Biotech stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PMCB, but not buy additional shares or sell existing shares. View analyst ratings for PharmaCyte Biotech or view top-rated stocks. How has PharmaCyte Biotech's stock price performed in 2022? PharmaCyte Biotech's stock was trading at $2.50 at the start of the year. Since then, PMCB stock has decreased by 10.4% and is now trading at $2.24. View the best growth stocks for 2022 here. How were PharmaCyte Biotech's earnings last quarter? PharmaCyte Biotech, Inc. (OTCMKTS:PMCB) released its quarterly earnings results on Wednesday, December, 15th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. View PharmaCyte Biotech's earnings history. Who are PharmaCyte Biotech's key executives? PharmaCyte Biotech's management team includes the following people: Mr. Kenneth L. Waggoner Esq., Chairman, CEO, Pres, Gen. Counsel & Sec. (Age 74, Pay $433.33k)Mr. Carlos A. Trujillo CPA, CPA, CFO & Director (Age 64, Pay $300k)Dr. Gerald W. Crabtree Ph.D., Chief Scientific Officer & Director (Age 81, Pay $94.33k)Dr. Jose L. Iglesias M.D., Consulting Chief Medical Officer (Age 65)Dr. Hans-Peter Hammes, Member of Medical & Scientific Advisory Board and Consultant Who are some of PharmaCyte Biotech's key competitors? Some companies that are related to PharmaCyte Biotech include Gritstone bio (GRTS), Dynamics Special Purpose (DYNS), CEL-SCI (CVM), CEL-SCI (CVM), Omega Therapeutics (OMGA), Graphite Bio (GRPH), Genfit (GNFT), INmune Bio (INMB), Poseida Therapeutics (PSTX), Jounce Therapeutics (JNCE), Ikena Oncology (IKNA), ARYA Sciences Acquisition Corp IV (ARYD), Fennec Pharmaceuticals (FENC), Taysha Gene Therapies (TSHA) and Finch Therapeutics Group (FNCH). View all of PMCB's competitors. What other stocks do shareholders of PharmaCyte Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other PharmaCyte Biotech investors own include Co-Diagnostics (CODX), iBio (IBIO), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), SANUWAVE Health (SNWV), Sierra Oncology (SRRA), OWC Pharmaceutical Research (OWCP), VBI Vaccines (VBIV) and Novavax (NVAX). What is PharmaCyte Biotech's stock symbol? PharmaCyte Biotech trades on the OTCMKTS under the ticker symbol "PMCB." How do I buy shares of PharmaCyte Biotech? Shares of PMCB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PharmaCyte Biotech's stock price today? One share of PMCB stock can currently be purchased for approximately $2.24. How much money does PharmaCyte Biotech make? PharmaCyte Biotech (OTCMKTS:PMCB) has a market capitalization of $46.41 million. How many employees does PharmaCyte Biotech have? PharmaCyte Biotech employs 4 workers across the globe. How can I contact PharmaCyte Biotech? PharmaCyte Biotech's mailing address is 23046 AVENIDA DE LA CARLOTA SUITE 600, LAGUNA HILLS CA, 92653. The official website for PharmaCyte Biotech is www.pharmacyte.com. The company can be reached via phone at (917) 595-2850, via email at info@pharmacyte.com, or via fax at 917-595-2851. This page (OTCMKTS:PMCB) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
